Pharmaceutical

CEPI provides $6.2m to push first mRNA-based Rift Valley fever vaccine into trial

Afrigen Biologics has secured a $6.2m grant from CEPI to develop the first mRNA-based vaccine against Rift Valley fever.

Jan 22, 2025 - 06:00
CEPI provides $6.2m to push first mRNA-based Rift Valley fever vaccine into trial
Afrigen Biologics has secured a $6.2m grant from CEPI to develop the first mRNA-based vaccine against Rift Valley fever.
Read the original article

Tags:

Previous Article

Active Pharmaceutical Ingredients and Intermediates for the Pharmaceutical Industry

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Absci and Caltech receive grant to develop HIV therapeutic vaccine

Absci and Caltech receive grant to develop HIV therapeu...

Aug 12, 2023

Debiopharm, SunRock sign agreement for cancer ADCs

Debiopharm, SunRock sign agreement for cancer ADCs

Sep 23, 2023

STAT+: Uninsured rate hits ‘record low’ — right before millions start losing Medicaid coverage

STAT+: Uninsured rate hits ‘record low’ — right before ...

Aug 3, 2023